Form 4: Zomedica Corp. Executive Russell Kevin Klass Reports Acquisition of Common Stock
SEC Form 4 Filing
Russell Kevin Klass, Sr Vice President of Sales at Zomedica Corp., reports acquiring 699,980 shares of common stock at $0.07 per share on March 17, 2025.
Summary
- On March 17, 2025, Russell Kevin Klass, Sr Vice President of Sales at Zomedica Corp., acquired 699,980 shares of common stock.
- The price per share was $0.07.
- Following the transaction, Klass directly owns 3,200,030 shares of Zomedica Corp. common stock.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a routine disclosure of an insider transaction. The sentiment is neither positive nor negative without additional context.
Industry Context
This is a standard SEC Form 4 filing, which is common for corporate insiders who trade in their company's stock. It provides transparency to the market regarding insider transactions.
Stakeholder Impact
- The transaction could have a minor impact on shareholder sentiment, depending on how the market interprets the insider's purchase.
Key Dates
| Date | Description |
|---|---|
| 03/17/2025 | Date of transaction: Russell Kevin Klass acquired common stock. |
| 03/18/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.